Analyst Ryan Zimmerman from BTIG maintained a Buy rating on Stryker and keeping the price target at $410.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ryan Zimmerman has given his Buy rating due to a combination of factors that highlight Stryker’s strong market position and growth potential. One of the key reasons is the company’s consistent ability to outperform the broader MedTech market, supported by its strategic focus on mergers and acquisitions and capital allocation priorities. Stryker’s management is expected to provide updates on these aspects during their upcoming Biennial Analyst Day, which could further reinforce investor confidence.
Additionally, Zimmerman’s valuation analysis supports the Buy rating, with a price target of $410 based on a multiple of 25.5 times the estimated earnings per share over the next 12 to 24 months. This valuation is higher than the average for large-cap peers, reflecting Stryker’s premium growth profile and strong execution history. The company’s robust free cash flow and healthy end-market demand also contribute to the positive outlook, suggesting that Stryker is well-positioned for continued success in the MedTech industry.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $450.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.